Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | ITK | Q08881 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486041 | 1.00 | PDCD1 (0.34) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL3486048 | 1.00 | PDCD1 (0.34) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL2227108 | 1.00 | PDCD1 (0.34) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL3485860 | 1.00 | PDCD1 (0.34) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL3485863 | 1.00 | PDCD1 (0.34) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL20893432 | 0.89 | MCHR1 (0.35) | ALDH1A1MCHR1 | |
| SCHEMBL16901703 | 0.84 | PDCD1 (0.35) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL2837931 | 0.84 | PDCD1 (0.35) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL16895689 | 0.84 | PDCD1 (0.35) | PDCD1CD274FGFR1FGFR4FGFR3 | |
| SCHEMBL2837932 | 0.84 | PDCD1 (0.35) | PDCD1CD274FGFR1FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-2519235-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-11-21 | — | — | EP | disclosed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8609679-B2 | 2,4-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8450335-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8338439-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PDCD1 1020/4885CD274 1948/4885FGFR1 421/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PDCD1 1020/4885CD274 1948/4885FGFR1 421/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | PDCD1 353/4885CD274 897/4885FGFR1 367/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PDCD1 4195/4885CD274 4234/4885FGFR1 3322/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PDCD1 1020/4885CD274 1948/4885FGFR1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.